Effect of cardiovascular drugs on the plasma levels of lipoprotein-associated phospholipase A2 (Lp-PLA2)

Open Clinical Chemistry Journal

Volumn 3, Issue SPEC. ISSUE 1, 2010, Pages 60-65

  Tsimihodimos, Vasilis ^a   Tselepis, Alexandros D ^b  

^a Medical School   (United States)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Cardiovascular drugs; Fibrates; Lipoprotein associated phospholipase A2; Statins

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN B; ATENOLOL; ATORVASTATIN; BENAZEPRIL; EPROSARTAN; ESTROGEN; EZETIMIBE; FATTY ACID; FENOFIBRATE; GLIPIZIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDAPAMIDE; LACIDIPINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYSOPHOSPHATIDYLCHOLINE; MESTRANOL; MEVINOLIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PIOGLITAZONE; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TETRAHYDROLIPSTATIN; VALSARTAN;

APHERESIS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CALORIC RESTRICTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; ENZYME ACTIVITY; ENZYME BINDING; FATTY ACID SYNTHESIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOTHYROIDISM; ISCHEMIC HEART DISEASE; LIPID OXIDATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 78249245115     PISSN: None     EISSN: 18742416     Source Type: Journal    
DOI: 10.2174/1874241601003020060     Document Type: Article

References (50)

1. Tselepis, A.D.; Chapman, M.J. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler. Suppl., 2002, 3, 57-68.
2. Tellis, C.C.; Tselepis, A.D. Tauhe role of lipoprotein-associated phospholipase A(2) in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim. Biophys. Acta, 2009, 1791, 327-338.
3. Okada, T.; Miyashita, M.; Kuromori, Y.; Iwata, F.; Harada, K.; Hattori, H. Platelet-activating factor acetylhydrolase concentration in children with abdominal obesity. Arterioscler. Thromb. Vasc. Biol., 2006, 26, e40-e41.
4. Detopoulou, P.; Nomikos, T.; Fragopoulou, E.; Panagiotakos, D.B.; Pitsavos, C.; Stefanadis, C.; Antonopoulou, S. Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, plateletactivating factor acetylhydrolase (PAF-AH) in leukocytes and body composition in healthy adults. Lipids Health Dis., 2009, 8, 19.
5. Zhang, B.; Fan, P.; Shimoji, E.; Itabe, H.; Miura, S.; Uehara, Y.; Matsunaga, A.; Saku, K. Modulating effects of cholesterol feeding and simvastatin treatment on platelet-activating factor acetylhydrolase activity and lysophosphatidylcholine concentration. Atherosclerosis, 2006, 186, 291-301.
6. Tzotzas, T.; Filippatos, T.D.; Triantos, A.; Bruckert, E.; Tselepis, A.D.; Kiortsis, D.N. Effects of a low-calorie diet associated with weight loss on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in healthy obese women. Nutr. Metab Cardiovasc. Dis., 2008, 18, 477-482.
7. Filippatos, T.D.; Gazi, I.F.; Liberopoulos, E.N.; Athyros, V.G.; Elisaf, M.S.; Tselepis, A.D.; Kiortsis, D.N. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis, 2007, 193, 428-437.
8. Wren, B.G. The benefits of oestrogen following menopause: why hormone replacement therapy should be offered to postmenopausal women. Med. J. Aust., 2009, 190, 321-325.
9. Xing, D.; Nozell, S.; Chen, Y.F.; Hage, F.; Oparil, S. Estrogen and mechanisms of vascular protection. Arterioscler. Thromb. Vasc. Biol., 2009, 29, 289-295.
10. Hodis, H.N. Assessing benefits and risks of hormone therapy in 2008: new evidence, especially with regard to the heart. Cleve. Clin. J. Med., 2008, 75 (Suppl. 4), S3-S12.
11. Yoshimura, T.; Ohshige, A.; Maeda, T.; Ito, M.; Okamura, H. Estrogen replacement therapy decreases platelet-activating factoracetylhydrolase activity in post-menopausal women. Maturitas, 1999, 31, 249-253.
12. Ohshige, A.; Ito, M.; Koyama, H.; Maeda, T.; Yoshimura, T.; Okamura, H. Effects of estrogen and progesterone on plateletactivating factor acetylhydrolase activity in ovariectomised rats. Artery, 1994, 21, 234-242.
13. Ohshige, A.; Ito, M.; Koyama, H.; Maeda, T.; Yoshimura, T.; Okamura, H. Effects of estrogen and progesterone on plasma platelet-activating factor-acetylhydrolase activity and low-density lipoprotein cholesterol concentration in men. Artery, 1996, 22, 115-124.
14. Biondi, B.; Cooper, D.S. The clinical significance of subclinical thyroid dysfunction. Endocr. Rev., 2008, 29, 76-131.
15. Fatourechi, V. Subclinical hypothyroidism: an update for primary care physicians. Mayo Clin. Proc., 2009, 84, 65-71.
16. Milionis, H.J.; Tambaki, A.P.; Kanioglou, C.N.; Elisaf, M.S.; Tselepis, A.D.; Tsatsoulis, A. Thyroid substitution therapy induces high-density lipoprotein-associated platelet-activating factoracetylhydrolase in patients with subclinical hypothyroidism: a potential antiatherogenic effect. Thyroid, 2005, 15, 455-460.
17. Satoh, K.; Imaizumi, T.; Kawamura, Y.; Yoshida, H.; Takamatsu, S.; Takamatsu, M. Increased activity of the platelet-activating factor acetylhydrolase in plasma low density lipoprotein from patients with essential hypertension. Prostaglandins, 1989, 37, 673-682.
18. Okumura, K.K.; Sagawa, N.; Kobayashi, F.; Nanno, H.; Matsumoto, T.; Itoh, H.; Korita, D.; Tanada, S.; Mori, T. Activity of platelet-activating-factor-acetylhydrolase and the nitric oxide metabolite level in the plasma of pregnant women who develop transient hypertension during later pregnancy. Reprod. Fertil. Dev., 1999, 11, 75-79.
19. Gu, Y.; Burlison, S.A.; Wang, Y. PAF levels and PAF-AH activities in placentas from normal and preeclamptic pregnancies. Placenta, 2006, 27, 744-749.
20. Rizos, E.C.; Spyrou, A.; Liberopoulos, E.N.; Papavasiliou, E.C.; Saougos, V.; Tselepis, A.D.; Elisaf, M. Effects of eprosartan on serum metabolic parameters in patients with essential hypertension. Open Cardiovasc. Med. J., 2007, 1, 22-26.
21. Spirou, A.; Rizos, E.; Liberopoulos, E.N.; Kolaitis, N.; Achimastos, A.; Tselepis, A.D.; Elisaf, M. Effect of barnidipine on blood pressure and serum metabolic parameters in patients with essential hypertension: a pilot study. J. Cardiovasc. Pharmacol. Ther., 2006, 11, 256-261.
22. Tambaki, A.P.; Rizos, E.; Tsimihodimos, V.; Tselepis, A.D.; Elisaf, M. Effects of antihypertensive and hypolipidemic drugs on plasma and high-density lipoprotein-associated platelet activating factor-acetylhydrolase activity. J. Cardiovasc. Pharmacol. Ther., 2004, 9, 91-95.
23. Kudolo, G.B.; Bressler, P.; DeFronzo, R.A. Plasma PAF acetylhydrolase in non-insulin dependent diabetes mellitus and obesity: effect of hyperinsulinemia and lovastatin treatment. J. Lipid Mediat. Cell Signal., 1997, 17, 97-113.
24. Serban, M.; Tanaseanu, C.; Kosaka, T.; Vidulescu, C.; Stoian, I.; Marta, D.S.; Tanaseanu, S.; Moldoveanu, E. Significance of platelet-activating factor acetylhydrolase in patients with noninsulin-dependent (type 2) diabetes mellitus. J. Cell Mol. Med., 2002, 6, 643-647.
25. Iwase, M.; Sonoki, K.; Sasaki, N.; Ohdo, S.; Higuchi, S.; Hattori, H.; Iida, M. Lysophosphatidylcholine contents in plasma LDL in patients with type 2 diabetes mellitus: relation with lipoproteinassociated phospholipase A2 and effects of simvastatin treatment. Atherosclerosis, 2008, 196, 931-936.
26. de Castro, S.H.; Faria Neto, H.C.; Gomes, M.B. Platelet-activating factor acetylhydrolase (PAF-AH) activity in patients with type 1 diabetes mellitus. Arq Bras. Cardiol., 2007, 88, 179-184.
27. Gomes, M.B.; Cobas, R.A.; Nunes, E.; Nery, M.; Castro-Faria-Neto, H.C.; Tibirica, E. Serum platelet-activating factor acetylhydrolase activity: a novel potential inflammatory marker in type 1 diabetes. Prostaglandins Other Lipid Mediat., 2008, 87, 42-46.
28. Gomes, M.B.; Cobas, R.A.; Nunes, E.; Castro-Faria-Neto, H.C.; da Matta, M.F.; Neves, R.; Tibirica, E. Plasma PAF-acetylhydrolase activity, inflammatory markers and susceptibility of LDL to in vitro oxidation in patients with type 1 diabetes mellitus. Diabetes Res. Clin. Pract., 2009, 85, 61-68.
29. Sanchez-Quesada, J.L.; Benitez, S.; Perez, A.; Wagner, A.M.; Rigla, M.; Carreras, G.; Vila, L.; Camacho, M.; Arcelus, R.; Ordonez-Llanos, J. The inflammatory properties of electronegative low-density lipoprotein from type 1 diabetic patients are related to increased platelet-activating factor acetylhydrolase activity. Diabetologia, 2005, 48, 2162-2169.
30. Basu, A.; Jensen, M.D.; McCann, F.; Nandy, D.; Mukhopadhyay, D.; McConnell, J.P.; Rizza, R.A. Lack of an effect of pioglitazone or glipizide on lipoprotein-associated phospholipase A2 in type 2 diabetes. Endocr. Pract., 2007, 13, 147-152.
31. Sumita, C.; Maeda, M.; Fujio, Y.; Kim, J.; Fujitsu, J.; Kasayama, S.; Yamamoto, I.; Azuma, J. Pioglitazone induces plasma platelet activating factor-acetylhydrolase and inhibits platelet activating factor-mediated cytoskeletal reorganization in macrophage. Biochim. Biophys. Acta, 2004, 1673, 115-121.
32. Mills, E.J.; Rachlis, B.; Wu, P.; Devereaux, P.J.; Arora, P.; Perri, D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J. Am. Coll. Cardiol., 2008, 52, 1769-1781.
33. Baigent, C.; Keech, A.; Kearney, P.M.; Blackwell, L.; Buck, G.; Pollicino, C.; Kirby, A.; Sourjina, T.; Peto, R.; Collins, R.; Simes, R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet, 2005, 366, 1267-1278.
34. Athyros, V.G.; Kakafika, A.I.; Tziomalos, K.; Karagiannis, A.; Mikhailidis, D.P. Pleiotropic effects of statins--clinical evidence. Curr. Pharm. Des., 2009, 15, 479-489.
35. Tsimihodimos, V.; Karabina, S.A.; Tambaki, A.P.; Bairaktari, E.; Goudevenos, J.A.; Chapman, M.J.; Elisaf, M.; Tselepis, A.D. Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler. Thromb. Vasc. Biol., 2002, 22, 306-311.
36. Saougos, V.G.; Tambaki, A.P.; Kalogirou, M.; Kostapanos, M.; Gazi, I.F.; Wolfert, R.L.; Elisaf, M.; Tselepis, A.D. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler. Thromb. Vasc. Biol., 2007, 27, 2236-2243.
37. Winkler, K.; Abletshauser, C.; Friedrich, I.; Hoffmann, M.M.; Wieland, H.; Marz, W. Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolase activity: a placebo-controlled trial in patients with type 2 diabetes. J. Clin. Endocrinol. Metab, 2004, 89, 1153-1159.
38. O'Donoghue, M.; Morrow, D.A.; Sabatine, M.S.; Murphy, S.A.; McCabe, C.H.; Cannon, C.P.; Braunwald, E. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation, 2006, 113, 1745-1752.
39. Schaefer, E.J.; McNamara, J.R.; Asztalos, B.F.; Tayler, T.; Daly,.A.; Gleason, J.L.; Seman, L.J.; Ferrari, A.; Rubenstein, J.J. Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects. Am. J. Cardiol., 2005, 95, 1025-1032.
40. Ky, B.; Burke, A.; Tsimikas, S.; Wolfe, M.L.; Tadesse, M.G.; Szapary, P.O.; Witztum, J.L.; FitzGerald, G.A.; Rader, D.J. The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. J. Am. Coll. Cardiol., 2008, 51, 1653-1662.
41. Kom, G.D.; Schwedhelm, E.; Maas, R.; Schneider, L.; Benndorf, R.; Boger, R.H. Impact of atorvastatin treatment on platelet-activating factor acetylhydrolase and 15-F(2trans)-isoprostane in hypercholesterolaemic patients. Br. J. Clin. Pharmacol., 2007, 63, 672-679.
42. Tsimihodimos, V.; Liberopoulos, E.; Elisaf, M. Pleiotropic effects of fenofibrate. Curr. Pharm. Des, 2009, 15, 517-528.
43. Tsimihodimos, V.; Kakafika, A.; Tambaki, A.P.; Bairaktari, E.; Chapman, M.J.; Elisaf, M.; Tselepis, A.D. Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins. J. Lipid Res., 2003, 44, 927-934.
44. Rosenson, R.S. Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome. Am. Heart J., 2008, 155, 499-16.
45. Muhlestein, J.B.; May, H.T.; Jensen, J.R.; Horne, B.D.; Lanman, R.B.; Lavasani, F.; Wolfert, R.L.; Pearson, R.R.; Yannicelli, H.D.; Anderson, J.L. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J. Am. Coll. Cardiol., 2006, 48, 396-401.
46. Filippatos, T.D.; Mikhailidis, D.P. Lipid-lowering drugs acting at the level of the gastrointestinal tract. Curr. Pharm. Des, 2009, 15, 490-516.
47. Kuvin, J.T.; Dave, D.M.; Sliney, K.A.; Mooney, P.; Patel, A.R.; Kimmelstiel, C.D.; Karas, R.H. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am. J. Cardiol., 2006, 98, 743-745.
48. Schmidt, E.B.; Koenig, W.; Khuseyinova, N.; Christensen, J.H. Lipoprotein-associated phospholipase A2 concentrations in plasma are associated with the extent of coronary artery disease and correlate to adipose tissue levels of marine n-3 fatty acids. Atherosclerosis, 2008, 196, 420-424.
49. Pedersen, M.W.; Koenig, W.; Christensen, J.H.; Schmidt, E.B. The effect of marine n-3 fatty acids in different doses on plasma concentrations of Lp-PLA2 in healthy adults. Eur. J. Nutr., 2009, 48, 1-5.
50. Moriarty, P.M.; Gibson, C.A. Effect of low-density lipoprotein apheresis on lipoprotein-associated phospholipase A2. Am. J. Cardiol., 2005, 95, 1246-1247.